Trastuzumab biosimilar - Shanghai Institute of Biological Products
Alternative Names: Herceptin Biosimilar- Shanghai Institute of Biological Products; SIBP 01Latest Information Update: 22 Apr 2022
At a glance
- Originator Shanghai Institute of Biological Products
- Developer Fudan University; Shanghai Institute of Biological Products
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HER2 positive breast cancer
Most Recent Events
- 22 Apr 2022 No development reported - Phase-III for HER2-positive-breast-cancer (Combination therapy) in China (IV) (NCT03989037)
- 18 Jun 2019 Phase-III clinical trials in HER2-positive-breast-cancer (Combination therapy) in China (IV) (NCT03989037)